First Capital Bank (FCB) first-half (H1) profit has jumped by 300 percent to K50.5 billion from K16.7 billion in June 2024 ...

The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection ...

This week, The PIE spent five minutes with Hitesh Parashar, chief business officer at Credila Financial Services.

Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitis Updated ...

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging ...

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study ...

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed or refractory hematologic malignancies, offering remarkable remis ...

Bispecific antibodies have ushered in a transformative era in treating non–small cell lung cancer (NSCLC), enabling dual-pathway targeting with promising clinical outcomes in previously refractory ...

Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes ...